Chlorphenoxamine (free base)

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 413158

CAS#: 77-38-3 (free base)

Description: Chlorphenoxamine (free base) is an antihistamine and anticholinergic used as an antipruritic and antiparkinsonian agent. It is an analog of diphenhydramine.

Chemical Structure

img
Chlorphenoxamine (free base)
CAS# 77-38-3 (free base)
Instruction

Theoretical Analysis

MedKoo Cat#: 413158
Name: Chlorphenoxamine (free base)
CAS#: 77-38-3 (free base)
Chemical Formula: C18H22ClNO
Exact Mass: 303.14
Molecular Weight: 303.830
Elemental Analysis: C, 71.16; H, 7.30; Cl, 11.67; N, 4.61; O, 5.27

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Chlorphenoxamine (free base); BRN2057618; BRN-2057618; BRN 2057618

IUPAC/Chemical Name: Ethanamine, 2-(1-(4-chlorophenyl)-1-phenylethoxy)-N,N-dimethyl-

InChi Key: KKHPNPMTPORSQE-UHFFFAOYSA-N

InChi Code: InChI=1S/C18H22ClNO/c1-18(21-14-13-20(2)3,15-7-5-4-6-8-15)16-9-11-17(19)12-10-16/h4-12H,13-14H2,1-3H3

SMILES Code: CC(C1=CC=CC=C1)(C2=CC=C(Cl)C=C2)OCCN(C)C

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 303.83 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: ULDALL PR, WALTON JN, NEWELL DJ. Chlorphenoxamine hydrochloride in parkinsonism. A controlled trial. Br Med J. 1961 Jun 10;1(5240):1649-52. doi: 10.1136/bmj.1.5240.1649. PMID: 13779077; PMCID: PMC1954253.

2: KERLEY TL, RICHARDS AB, BEGLEY RW, ABREU BE, WEAVER LC. Anticonvulsant and antitremor effects of chlorphenoxamine. J Pharmacol Exp Ther. 1961 Jun;132:360-5. PMID: 13752621.

3: Dinç E, Palabiyik IM, Ustündağ O, Yurtsever F, Onur F. Simultaneous spectrophotometric determination of chlorphenoxamine hydrochloride and caffeine in a pharmaceutical preparation using first derivative of the ratio spectra and chemometric methods. J Pharm Biomed Anal. 2002 May 15;28(3-4):591-600. doi: 10.1016/s0731-7085(01)00694-x. PMID: 12008138.

4: KERLEY TL, NEWBERNE JW, BRINKMAN DC, WEAVER LC. The acute and chronic toxicities of chlorphenoxamine. Toxicol Appl Pharmacol. 1962 Sep;4:638-49. doi: 10.1016/0041-008x(62)90091-1. PMID: 14455272.

5: DOSHAY LJ, CONSTABLE K. Treatment of paralysis agitans with chlorphenoxamine hydrochloride. J Am Med Assoc. 1959 May 2;170(1):37-41. doi: 10.1001/jama.1959.03010010039008. PMID: 13640980.

6: Köppel C, Tenczer J, Arndt I, Ibe K. Urinary metabolism of chlorphenoxamine in man. Arzneimittelforschung. 1987 Sep;37(9):1062-4. PMID: 2893627.

7: Strang RR. A clinical evaluation of chlorphenoxamine with caffeine in the treatment of Parkinson's disease, including a comparison with methixene. J Clin Pharmacol J New Drugs. 1967 Jul-Aug;7(4):214-20. doi: 10.1002/j.1552-4604.1967.tb00050.x. PMID: 5340692.

8: Kelani KM. Simultaneous determination of caffeine, 8-chlorotheophylline, and chlorphenoxamine hydrochloride in ternary mixtures by ratio-spectra zero- crossing first-derivative spectrophotometric and chemometric methods. J AOAC Int. 2005 Jul-Aug;88(4):1126-34. PMID: 16152931.

9: MAGEE KR, CURRIER RD. Treatment of Parkinson's disease with chlorphenoxamine. J Mich State Med Soc. 1960 Sep;59:1364-5. PMID: 13765186.

10: BAZEX A, DUPRE A, CHRISTOL B. [Trial treatment of urticaria with chlorphenoxamine]. Clinique (Paris). 1963 Jul-Aug;58:447-50. French. PMID: 13967113.